Why the study?
Does atorvastatin reduce adverse events and improve myocardial performance in outpatients with chronic heart failure and LVEF ≤40%?
Does atorvastatin reduce adverse events and improve myocardial performance in outpatients with chronic heart failure and LVEF ≤40%?
In outpatients with chronic heart failure and reduced ejection fraction, atorvastatin use is associated with improved left ventricular performance and reduced cardiac mortality.
No takes yet. Share an insight, caveat, or question.
Atorvastatin linked to lower cardiac death and better diastolic function in HFrEF outpatients; hypothesis-generating and requires RCT confirmation before practice change.
Correale et al. (2013) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: